The Tumor Antigen market is a subset of the Oncology Drugs market, which focuses on the development of drugs to treat cancer. Tumor antigens are molecules that are expressed on the surface of cancer cells and can be recognized by the immune system. These antigens can be used to develop drugs that target and destroy cancer cells, while leaving healthy cells unharmed. Tumor antigens can be used to develop vaccines, monoclonal antibodies, and other immunotherapies. These therapies can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
Some companies in the Tumor Antigen market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are actively researching and developing new treatments for cancer, including immunotherapies that target tumor antigens. Show Less Read more
